Clinical Trials Browser

MSI-H × sintilimab × 90 days × Clear all

NCT05890742 2026-05-28

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Phase 3 Active not recruiting

Other solid neoplasm

MSI-H